Ervexia Occupational Health vs Clearview Franchising

Clearview Franchising is the stronger software-sales opportunity right now, and it’s not close. The dimension that seals it is terrain: 12 total units with 8 franchised gives you a real, repeatable deal pattern. Ervexia’s 3 total units—only 1 franchised—is a consulting shop, not a franchise system. You can’t build a pipeline on 1 franchised location. Clearview’s 8 franchised units mean 8 distinct buying windows, 8 potential champions, and a legitimate shot at a land-and-expand motion inside a single brand.

The tradeoff is budget quality. Ervexia’s investment range stretches to $422K, which signals deeper-pocketed operators who might buy a full stack without flinching. Clearview’s cap is $115K—tight, but not disqualifying for POS, scheduling, and back-office. And that $20 royalty on a financial-services concept tells you these are high-margin, transaction-heavy locations where software that captures revenue or reduces labor leakage pays for itself fast. You’re not selling to a franchisee who’s scraping by; you’re selling to one who’s giving up 20% because the unit economics work.

Timing is the hidden accelerator. Clearview’s FDD is marked DUE—2025 filing. That means the franchisor is actively updating disclosures, likely refreshing tech stacks or supplier lists as part of the renewal. You walk in now, you’re part of the refresh conversation, not a cold pitch six months after the ink dries. Ervexia’s CURRENT 2026 filing is a compliance win, not a sales window.

Verdict: Clearview’s 8 franchised units, high-margin royalty structure, and imminent FDD refresh make it the only brand here with a real pipeline—Ervexia is a wait-and-see account, not a territory.